Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database by Kimura, Goji et al.
TitleAntipsychotics-Associated Serious Adverse Events inChildren: An Analysis of the FAERS Database
Author(s)
Kimura, Goji; Kadoyama, Kaori; Brown, J.B.; Nakamura,
Tsutomu; Miki, Ikuya; Nisiguchi, Kohshi; Sakaeda, Toshiyuki;
Okuno, Yasushi




© Ivyspring International Publisher. This is an open-access
article distributed under the terms of the Creative Commons
License (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Reproduction is permitted for personal, noncommercial use,










International Journal of Medical Sciences 
2015; 12(2): 135-140. doi: 10.7150/ijms.10453 
Research Paper 
Antipsychotics-Associated Serious Adverse Events in 
Children: An Analysis of the FAERS Database 
Goji Kimura 1, Kaori Kadoyama 1, J.B. Brown 2, Tsutomu Nakamura 3, Ikuya Miki 3, Kohshi Nisiguchi 3, 4, 
Toshiyuki Sakaeda 1, 4 , and Yasushi Okuno 2 
1. Center for Integrative Education in Pharmacy and Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyoto Uni-
versity, Kyoto 606-8501, Japan 
2. Department of Clinical System Onco-Informatics, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan 
3. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan 
4. Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan 
 Corresponding author: Kaori Kadoyama, Ph.D., Center for Integrative Education in Pharmacy and Pharmaceutical Sciences, Graduate 
School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan, Tel.: +81-75-753-4522, Fax: +81-75-753-9253, e-mail: 
kao-kado@pharm.kyoto-u.ac.jp; Yasushi Okuno, Ph.D., Department of Clinical System Onco-Informatics, Graduate School of Medicine, 
Kyoto University, Kyoto 606-8501, Japan, Tel.&Fax: +81-75-753-4559, e-mail: okuno@pharm.kyoto-u.ac.jp 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2014.09.01; Accepted: 2014.12.10; Published: 2015.01.05 
Abstract 
Objective: The reports submitted to the US Food and Drug Administration (FDA) Adverse Event 
Reporting System (FAERS) from 1997 to 2011 were reviewed to assess serious adverse events 
induced by the administration of antipsychotics to children.  
Methods: Following pre-processing of FAERS data by elimination of duplicated records as well as 
adjustments to standardize drug names, reports involving haloperidol, olanzapine, quetiapine, 
clozapine, ziprasidone, risperidone, and aripiprazole were analyzed in children (age 0-12). Signals in 
the data that signified a drug-associated adverse event were detected via quantitative data mining 
algorithms. The algorithms applied to this study include the empirical Bayes geometric mean, the 
reporting odds ratio, the proportional reporting ratio, and the information component of a 
Bayesian confidence propagation neural network. Neuroleptic malignant syndrome (NMS), QT 
prolongation, leukopenia, and suicide attempt were focused on as serious adverse events. 
Results: In regard to NMS, the signal scores for haloperidol and aripiprazole were greater than for 
other antipsychotics. Significant signals of the QT prolongation adverse event were detected only 
for ziprasidone and risperidone. With respect to leukopenia, the association with clozapine was 
noteworthy. In the case of suicide attempt, signals for haloperidol, olanzapine, quetiapine, 
risperidone, and aripiprazole were detected.  
Conclusions: It was suggested that there is a level of diversity in the strength of the association 
between various first- and second-generation antipsychotics with associated serious adverse 
events, which possibly lead to fatal outcomes. We recommend that research be continued in order 
to gather a large variety and quantity of related information, and that both available and newly 
reported data be placed in the context of multiple medical viewpoints in order to lead to improved 
levels of care. 
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Introduction 
Second-generation antipsychotic drugs (SGAs) 
are thought to provide different therapeutic outcomes 
from first-generation antipsychotic drugs (FGAs), due 
to their relatively low affinity for dopamine D2 re-
ceptors and affinities for other receptors. SGAs are 








and quality of life more than FGAs [1]. Medical doc-
tors understand that improved efficacy for these 
problems is a great advantage of SGAs; however, little 
information is available concerning their superiority 
[1]. Weight gain, hyperprolactinemia, and extrapy-
ramidal symptoms (EPS) are commonly found in pa-
tients treated with FGAs or SGAs [2-5]. Additionally, 
neuroleptic malignant syndrome (NMS), QT prolon-
gation, leukopenia, and suicidal behavior are reported 
for both [2-5]; however again, we do not have a con-
sensus on which is better. Additionally, in 2009, a 
meta-analysis was published to compare the safety 
and efficacy of FGAs and SGAs, in which 150 dou-
ble-blind studies were included with 21,533 partici-
pants [1]. The analysis concluded that SGAs differed 
in many properties and were not a homogenous class, 
strongly suggesting the importance of detailed inves-
tigation of each drug [1]. 
 Recently, the use of antipsychotics, especially 
SGAs, has been increasing in children. This is, in part, 
explained by their off-label uses, including those for 
Attention Deficit / Hyperactivity Disorder (ADHD) 
[6-8]. In the USA, the use of SGAs for children has 
been approved since 2006, and this has also contrib-
uted to the increase. The surveillance of adverse event 
reports submitted to the US Food and Drug Admin-
istration (FDA) Adverse Event Reporting System 
(FAERS) suggested that antipsychotics are included in 
the top 5 reported suspect therapeutic drug classes in 
children [9]. In this study, the FAERS database was 
used to assess the associations between 5 representa-
tive SGAs and adverse events in children. A FGA, 
haloperidol, and the recently developed aripiprazole 
were also subjected to the investigation, and we fo-
cused on 4 rare adverse events, including NMS, QT 
prolongation, leukopenia, and suicidal behavior. Data 
mining algorithms were used for the quantitative de-
tection of signals [10-18], where a signal means a sta-
tistical association between a drug and an adverse 
event or a drug-associated adverse event.  
Methods 
Data sources 
 Input data for this study were taken from the 
public release of the FAERS database, covering the 
period from the fourth quarter of 1997 through the 
third quarter of 2011. The total number of reports 
used was 4,671,217. Besides those from manufactures, 
reports can be submitted from health care profession-
als and the public. The database’s data structure ad-
heres to the international safety reporting guidance 
issued by the International Conference on Harmoni-
sation ICH E2B. A data set consists of 7 data tables: 
report sources (RPSR), patient demographic and ad-
ministrative information (DEMO), drug therapy start 
and end dates (THER), indications for use/diagnosis 
(INDI), drug/biologic information (DRUG), adverse 
events (REAC), and patient outcomes (OUTC). Pre-
ferred terms (PTs) in the Medical Dictionary for Reg-
ulatory Activities (MedDRA) serve as the terminology 
for registration of adverse events in REAC table. Here, 
version 16.1 of MedDRA was used.  
 Before data mining was executed, several 
pre-processing steps of FAERS were undertaken. 
First, duplicated reports, which appear with multiple 
CASE field values in the database, were filtered by 
applying the FDA’s recommendation of adopting the 
most recent CASE number. This processing step re-
duced the number of reports from 4,671,217 to 
3,472,494, a 25.7% reduction. Next, in order to account 
for registration of arbitrary drug names including 
trade names and abbreviations, which is permissible 
within the FAERS system, drug names were mapped 
into unified generic names via text mining. As a part 
of the standardization process, GNU Aspell was ap-
plied to detect spelling errors. Additionally, records of 
side effects that are not registered as associated with 
the use of a pharmaceutical, such as foods, beverages, 
or other medical treatments including radiation 
therapy were eliminated. Similarly, adverse event 
records with ambiguous drug names such as generic 
“beta blockers” were filtered out. As a final filter, only 
records were retained in which demographic infor-
mation indicated that children less than 12 years old 
were the recipients of treatment. After applying this 
pre-mining filter pipeline, the total number of reports 
used was 94,635. Consequently, a total of 1,098,811 
co-occurrences were found in 94,635 reports, where a 
co-occurrence was a pair constituting a drug and a 
drug-associated adverse event.  
Definition of adverse events  
 According to MedDRA version 16.1, NMS, QT 
prolongation, leukopenia, and suicide attempt are 
coded with preferred terms PT10029282, PT10014387, 
PT10024384, and PT10042464 with 7, 10, 5, and 5 
lower level of terms (LLTs) assigned, respectively.  
Signal Detection Data Mining 
 Once a collection of filtered adverse event rec-
ords are assembled, a key question is how to weight 
and extract meaningful events as adverse event sig-
nals. To this end, a number of algorithms have been 
developed, where the common element of the algo-
rithms is that signals are defined as those events re-
ported with a greater frequency than can be expected, 
given an estimated expectation for reporting fre-
quency derived from the drugs and ADRs (adverse 
drug reaction events) in the record collection to be 




analyzed [14-18]. The algorithms used in this study 
include: (1) the proportional reporting ratio (PRR) [10] 
which is used by the Medicines and Healthcare 
products Regulatory Agency (MHRA) in the UK; (2) 
the reporting odds ratio (ROR) [11] in use at the 
Netherlands Pharmacovigilance Centre; (3) the in-
formation component (IC) criteria [12] employed by 
the World Health Organization (WHO); (4) and the 
empirical Bayes geometric mean (EBGM) [13] which is 
a part of FDA analytical methods. 
 The PRR, ROR, IC, and EBGM methods all em-
ploy the use of 2x2 confusion matrices of drug-event 
counts; that is, a drug and an event are placed on the 
rows and columns of a matrix, and the frequency of 
the four possible outcomes is tabulated. Where the 
algorithms then differ is that IC and EBGM use 
Bayesian reasoning, while the PRR and ROR methods 
take the frequentist approach to statistical inference. 
Readers are encouraged to consult the references of 
each method to obtain extended details. 
 Here, we summarize the ways in which each test 
uses its reasoning and formulation to “detect” a sig-
nal. First we consider the classical, frequentist statis-
tical approaches. In the PRR method, a signal is de-
tected if the number of co-occurrences is 3 or more, 
and additionally, if the PRR is 2 or more with an as-
sociated χ2 value of 4 or more [10]. Using ROR, when 
the lower bound of the 95% two-sided confidence 
interval exceeds 1, it is an indication of an ADR signal 
[11]. 
 Next, we consider the Bayesian methods for 
signal detection. The IC algorithm performs signal 
detection via the IC025 metric, which is a lower bound 
of the 95% two-sided confidence interval of IC, with 
an ADR signal indicated by the IC025 value exceeding 
0 [12]. For the EGBM method, a lower one-sided 95% 
confidence bound of the EBGM, termed the EB05 
metric, is used; EB05 is greater than or equal to 2.0 
results in an ADR signal [13].  
Finally, we need a criterion to unite our use of 
the various signal detection methods. In this study, 
we elect for the most direct, simple strategy: an ad-
verse event is drug-associated when at least 1 of the 4 
algorithms meets its above criteria for signal detec-
tion. 
Results 
 The total number of drug and reported adverse 
event co-occurrences with haloperidol was 1,600, with 
2,802 for olanzapine, 2,440 for quetiapine, 519 for 
clozapine, 623 for ziprasidone, 5,219 for risperidone, 
and 2,553 for aripiprazole, representing 0.146%, 
0.255%, 0.222%, 0.047%, 0.056%, 0.475%, and 0.232% 
of all co-occurrences in children in the filtered data-
base, respectively. In total, 181, 345, 313, 119, 139, 380, 
and 269 adverse events were extracted as antipsy-
chotics-associated adverse events with 999, 1,644, 
1,386, 310, 361, 3,104, and 1,530 co-occurrences with a 
signal detected, respectively. 
 The signals for NMS were detected with the 5 
antipsychotics other than clozapine and ziprasidone, 
and signal scores for haloperidol and aripiprazole 
were greater than for other antipsychotics in Table 1. 
As for QT prolongation, signals were detected for 
only ziprasidone and risperidone, and signal scores 
suggested a stronger association for ziprasidone (Ta-
ble 2). The signal scores for leukopenia are listed in 
Table 3. Although signals were detected for quetiap-
ine, clozapine, and risperidone, the association with 
clozapine was noteworthy. Table 4 shows the signal 
scores for suicide attempt, and signals for 5 antipsy-
chotics; haloperidol, olanzapine, quetiapine, risperi-




Table 1. Signal scores for antipsychotics-associated neuroleptic malignant syndrome. 








Haloperidol 8 26.92 (174.0)* 27.98 (13.77, 42.18)* 2.71 (1.72, 3.71)* 22.97 (12.11)* 
Olanzapine 3 5.74 (7.5)* 5.81 (1.86, 9.77)* 1.21 (-0.31, 2.73) 2.27 (0.83) 
Quetiapine 8 17.62 (109.2)* 18.30 (9.02, 27.59)* 2.55 (1.56, 3.54)* 15.03 (6.97)* 
Clozapine N.A.     
Ziprasidone N.A.     
Risperidone 10 10.28 (75.0)* 10.76 (5.70, 15.83)* 2.41 (1.52, 3.31)* 8.15 (3.79)* 
Aripiprazole 14 29.54 (357.0)* 31.64 (18.36, 44.92)* 3.30 (2.53, 4.07)* 26.82 (16.85)* 
N: the number of co-occurrences. N.A.: Not Available 
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean. CI: the confidence interval 
(two-sided for ROR and IC, and one-sided for EBGM). 
An asterisk (*) indicates a statistically significant association, i.e., the adverse events are detected as signals. 
 
 




Table 2. Signal scores for antipsychotics-associated QT prolongation. 








Haloperidol 2 1.41 (0.0) 1.41 (0.35, 2.47) 0.06 (-1.72, 1.84) 0.97 (0.31) 
Olanzapine 1 0.40 (0.4) 0.40 (0.06, 0.75) -1.19 (-3.46, 1.08) 0.40 (0.09) 
Quetiapine 3 1.39 (0.1) 1.39 (0.45, 2.33) 0.15 (-1.36, 1.66) 1.05 (0.41) 
Clozapine N.A.     
Ziprasidone 15 27.83 (353.1)* 28.25 (16.86, 39.64)* 3.32 (2.59, 4.05)* 25.07 (16.02)* 
Risperidone 9 1.95 (3.3) 1.96 (1.02, 2.90)* 0.76 (-0.16, 1.68) 1.65 (0.94) 
Aripiprazole 3 1.33 (0.1) 1.33 (0.43, 2.20) 0.11 (-1.40, 1.62) 1.02 (0.39) 
N: the number of co-occurrences. N.A.: Not Available 
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean. CI: the confidence interval 
(two-sided for ROR and IC, and one-sided for EBGM). 
An asterisk (*) indicates a statistically significant association, i.e., the adverse events are detected as signals. 
 
Table 3. Signal scores for antipsychotics-associated leukopenia  








Haloperidol N.A.     
Olanzapine 2 0.82 (0.0) 0.83 (0.21, 1.45) -0.44 (-2.22, 1.34) 0.69 (0.22) 
Quetiapine 11 5.25 (33.6)* 5.30 (2.92, 7.68)* 1.89 (1.05, 2.73)* 3.77 (2.19)* 
Clozapine 8 18.15 (111.3)* 18.30 (9.07, 27.52)* 2.56 (1.57, 3.54)* 15.33 (27.65)* 
Ziprasidone N.A.     
Risperidone 9 2.00 (3.6) 2.01 (1.04, 2.98)* 0.79 (-0.13, 1.71) 1.68 (0.96) 
Aripiprazole 2 0.91 (0.0) 0.91 (0.23, 1.59) -0.35 (-2.13, 1.43) 0.74 (0.24) 
N: the number of co-occurrences. N.A.: Not Available 
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean. CI: the confidence interval 
(two-sided for ROR and IC, and one-sided for EBGM). 
An asterisk (*) indicates a statistically significant association, i.e., the adverse events are detected as signals. 
 
Table 4. Signal scores for antipsychotic-associated suicide attempt. 








Haloperidol 5 9.36 (29.4)* 9.47 (3.91, 15.03)* 1.84 (0.63, 3.06)* 4.65 (1.75) 
Olanzapine 10 10.69 (78.3)* 10.96 (5.84, 16.08)* 2.44 (1.55, 3.32)* 8.56 (3.97)* 
Quetiapine 6 7.36 (26.9)* 7.46 (3.33, 11.60)* 1.84 (0.72, 2.96)* 4.03 (1.79) 
Clozapine N.A.     
Ziprasidone 1 4.80 (0.4) 4.81 (0.67, 8.94) 0.34 (-1.94, 2.62) 1.15 (0.25) 
Risperidone 13 7.45 (66.5)* 7.69 (4.41, 10.96)* 2.30 (1.51, 3.08)* 5.75 (3.24)* 
Aripiprazole 4 4.68 (8.2)* 4.72 (1.76, 7.69)* 1.28 (-0.06, 2.62) 2.36 (1.00) 
N: the number of co-occurrences. N.A.: Not Available 
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean. CI: the confidence interval 
(two-sided for ROR and IC, and one-sided for EBGM). 




 According to some recent reports, number of 
prescriptions for antipsychotics among younger pa-
tients has been increasing [6-8]. Furthermore, the 
Guideline “Clinical Investigation of Medicinal Prod-
ucts in the Pediatric Population” [19], which was de-
veloped by the ICH expert working group, catego-
rized “children” as 2 to 11 years. Therefore, in this 
study, we focused on children less than 12 years old.  
 NMS is a rare, but potentially fatal complication 
of treatment with antipsychotic medication and is 
characterized by the development of severe muscle 
rigidity and hyperthermia, first described by Delay et 
al. in 1968 [20]. In spite of the long period of time since 
the first description, to the best of our knowledge, 
there have been few reports concerning the associa-
tion between SGAs and NMS in children. In our 
study, signals were detected for 5 antipsychotics, i.e., 
haloperidol, quetiapine, ziprasidone, risperidone, and 
aripiprazole (Table 1). Signal scores were higher for 
haloperidol and aripiprazole than for the other anti-
psychotics, suggesting that SGAs show lower suscep-
tibility to NMS. The precise pathophysiology of NMS 
remains unknown. It has been suggested that NMS is 
the result of dopamine D2 receptor blockade [20-22], 
whereas, dopamine D2 receptor antagonism does not 
fully explain all of the signs and symptoms of NMS 
[22]. According to antipsychotic receptor-binding 
profiles, relative affinities for the dopamine D2 re-




ceptor of haloperidol and aripiprazole are higher, and 
those of quetiapine and risperidone are lower [4, 21]. 
Moreover, aripiprazole controls the dopaminergic 
function by acting as a partial agonist of dopamine D2 
receptor subtypes, while high concentrations of ari-
piprazole induce dopaminergic blockade [4]. There-
fore, our observation may be partially attributed to 
these drug action mechanisms.  
 QT prolongation is also a serious adverse event 
accompanying the administration of SGAs, and re-
sults from blockade of the delayed rectifier potassium 
current (IKr). It is associated with presyncope, syn-
cope, polymorphic ventricular tachycardia, the sub-
type torsade de pointes, and sudden cardiac death 
[23]. Poluzzi et al. reported the torsadogenic risk of 
antipsychotics including QT prolongation using 
FAERS [24], and Wenzel-Seifert et al. suggested that 
QT prolongation occurs most significantly with 
ziprasidone in SGAs [25]. However, neither of them 
provided data after stratifying by age. Here, the sig-
nals for QT prolongation were detected for ziprasi-
done and risperidone, with the signal score being 
higher for the former than the latter (Table 2). In this 
study, it was confirmed that ziprasidone is most 
strongly associated with QT prolongation in children.  
 Hematologic abnormalities induced by anti-
psychotics may be life-threatening in some patients. 
Several studies revealed the association between 
clozapine and leukopenia in children, and clozapine is 
generally recommended for drug-resistant cases 
[26-28]. In addition, Etain et al. reported that leuko-
penia was induced by risperidone [29]. Our results 
reproduced these observations, but the signal was 
also detected for quetiapine (Table 3).  
 The incidence of suicide attempt is more fre-
quent in individuals with schizophrenia than in gen-
eral [30, 31]. Previous studies suggested that the sui-
cide risk differs among antipsychotics [30-33]; how-
ever, the impact of antipsychotics on suicide attempt 
has been a matter of controversy. Moreover, adher-
ence to antipsychotics is likely to reduce the suicide 
risk [30], so suicide attempt in individuals who take 
antipsychotics may be due to weakness of efficacy. On 
the other hand, an adverse event is generally defined 
as any untoward medical occurrence in a patient or 
clinical investigation subject administered a pharma-
ceutical product and which does not necessarily have 
to have a causal relationship with this treatment [34]. 
Therefore, in this study, we regarded suicide attempt 
accompanied with the administration of antipsychot-
ics as adverse events even if it derives from weakness 
of efficacy, and FAERS database was reviewed in or-
der to confirm if the suicide risk differs among anti-
psychotics and is associated with them. As a result, 
signals were detected for antipsychotics other than 
clozapine and ziprasidone, and the scores were higher 
for olanzapine and risperidone (Table 4). Tiihonen et 
al. revealed that use of clozapine might be more ef-
fective than that of other antipsychotics for reducing 
suicidal attempt [30]. This might have contributed to 
the lack of a signal detection for clozapine.  
 In conclusion, reports in the FAERS database 
were reviewed to assess the antipsychotics-associated 
serious adverse events in children. Based on 94,635 
reports from 1997 to 2011, it was suggested that there 
is a level of diversity in the strength of the association 
between various first- and second-generation anti-
psychotics with associated serious adverse events, 
which possibly lead to fatal outcomes. We recom-
mend that research be continued in order to gather a 
large variety and quantity of related information, and 
that both available and newly reported data be placed 
in the context of multiple medical viewpoints in order 
to lead to improved levels of care. 
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